Biocept, Inc.
BIOC
BIOC was delisted on the 24th of October, 2023.
27 hedge funds and large institutions have $1.78M invested in Biocept, Inc. in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 5 closing their positions.
1,354% more call options, than puts
Call options by funds: $189K | Put options by funds: $13K
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
64% less capital invested
Capital invested by funds: $4.9M → $1.78M (-$3.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$157K |
| 2 |
Renaissance Technologies
New York
|
+$89.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$44.2K |
| 4 |
VF
Virtu Financial
New York
|
+$42.8K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$23.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$272K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$215K |
| 3 |
JP Morgan Chase
New York
|
-$189K |
| 4 |
PP
PDT Partners
New York
|
-$83K |
| 5 |
BlackRock
New York
|
-$63.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Marshall Wace
London,
United Kingdom
| – | -$215K | -3,094 | Closed |
|
|
27
JP Morgan Chase
New York
| – | -$189K | -2,712 | Closed |
|
|
PP
28
PDT Partners
New York
| – | -$83K | -1,188 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$5K | -71 | Closed |
|
30
Morgan Stanley
New York
| – | -$4K | -63 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | +$46 | +1 | +33% |
|
BIOC Hedge Fund Activity: Q2 2022 in Review
27 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q2 2022, worth a combined $1.78M — down 64% from $4.9M a quarter earlier.
Fund positioning in BIOC was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $157K. The largest seller was Ameriprise, cutting an estimated $272K.
- 27 institutional investors held Biocept, Inc. (BIOC) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.78M of Biocept, Inc. stock for Q2 2022, down 64% quarter-over-quarter.
- 5 funds opened new Biocept, Inc. positions in Q2 2022 and 5 closed out, a net change of 0 holders.
- The largest Biocept, Inc. buyer in Q2 2022 was Millennium Management, an estimated $157K added.
- The largest Biocept, Inc. seller in Q2 2022 was Ameriprise, an estimated $272K sold.
Based on aggregated 13F filings for Q2 2022.